Pulmonary hypertension: The future has begun;Pulmonale hypertonie: Die zukunft hat begonnen

Medizinische Klinik

Volumn 101, Issue 4, 2006, Pages 328-333

  Olschewski, Horst ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

EGF receptor blocker; Endothelin receptor antagonist; PDGF receptor blocker; Phosphodiesterase 5 inhibitor; Prostanoid; Pulmonary arterial hypertension; Pulmonary hypertension; Tyrosine kinase inhibitor

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR ANTAGONIST; PROSTACYCLIN; PROSTANOID; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; RHO KINASE INHIBITOR; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE;

AWARENESS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SCREENING; DRUG TARGETING; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HEALTH PROGRAM; HUMAN; MEDICAL RESEARCH; PATHOLOGY; PULMONARY HYPERTENSION; REVIEW; SENSITIVITY AND SENSIBILITY;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FORECASTING; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; PROTEIN-TYROSINE KINASES; PULMONARY ARTERY; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ENDOTHELIN; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; TIME FACTORS;

EID: 33645766752     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-006-1042-8     Document Type: Review

References (52)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:Suppl S:5S-12S.
2. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
3. Channick R, Badesch DB, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001;20:262-3.
4. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
5. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of padents started on i.v. epoprostenol. Thorax 2005;60:1025-30.
6. Sitbon O, Gressin V, Speich R, et al. Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-7.
7. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-8.
8. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
9. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
10. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
11. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
12. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7.
13. Gomberg-Maitland M, Tapson VE, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005;172:1586-9.
14. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
15. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
16. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
17. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-53.
18. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
19. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46.
20. Voswinckel R, Ghofrani HA, Grimminger E, et al. Inhaled trepostinil for treatment of chronic pulmonary arterial hypertension. Ann Intern Med 2006;144:149-50.
21. Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1361-8.
22. Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
23. Ghofrani HA, Rose F, Schermuly RT, et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002;30:2489-92.
24. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
25. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64.
26. Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22:330-4.
27. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-10.
28. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-9.
29. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5.
30. Gomberg-Maitland M, McLaughlin V, Gulati M. et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005;96:1334-6.
31. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63.
32. Gaine S, Rubin L. Primary pulmonary hypertension. Lancet 1998;352:719-25.
33. McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91.
34. Balasubramaniam V, le Cras TD, Ivy DD, et al. Role of platelet derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003;284:L826-33.
35. Merklinger SL, Jones PL, Martinez EC, et al. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005;112:423-31.
36. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
37. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3.
38. Hoshino S, Yoshida M, Inoue K, et al. Cigarette smoke extract induces endothelial cell injury via JNK pathway. Biochem Biophys Res Commun 2005;329:58-63.
39. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905.
40. Sakao S, Taraseviciene-Stewart L, Lee JD, et al. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19:1178-80.
41. Sakao S, Taraseviciene-Stewart L, Lee JD, et al. Vascular endothelial growth factor receptor blockade by SU5416 combined with pulsatile shear stress causes apoptosis and subsequent proliferation of apoptosis-resistant endothelial cells. Chest 2005;128:Suppl:610S-1S.
42. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005;171:734-42.
43. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-indnced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987-93.
44. Pullamsetti S, Kiss L, Ghofrani HA, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005;19:1175-7.
45. Hyvelin JM, Howell K, Nichol A, et al. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005;97:185-91.
46. Rabinovitch M. Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 2001;22:433-49, viii.
47. Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63.
48. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:2812-9.
49. Hong Z, Weir EK, Nelson DP, et al. Subacute hypoxia decreases voltage-activated potassium channel expression and function in pulmonary artery myocytes. Am J Respir Cell Mol Biol 2004;31:337-43.
50. Grunig E, Dehnert C, Mereles D, et al. Enhanced hypoxic pulmonary vasoconstriction in families of adults or children with idiopathic pulmonary arterial hypertension. Chest 2005;128:Suppl:630S-3S.
51. Grunig E, Janssen B, Mereles D, et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000;102:1145-50.
52. Grunig E, Mereles D, Hildebrandt W, et al. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol 2000;35:980-7.